^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RAS mutation

    1d
    LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation (clinicaltrials.gov)
    P1/2, N=99, Not yet recruiting, Luye Pharma Group Ltd.
    New P1/2 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
    1d
    RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=28, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (RP-6306) • camonsertib (RP-3500)
    1d
    Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study. (PubMed, ESMO Gastrointest Oncol)
    Between mCRC diagnosis and death or withdrawal, patients were frequently exposed to fluoropyrimidine (99.0%), irinotecan (96.2%), oxaliplatin (88.4%), anti-vascular endothelial growth factor (78.7%) and anti-epidermal growth factor receptor (40.1%). PROMETCO provided information on real-world prescribing patterns and efficacy. OS from mCRC diagnosis and PFS from 3L and beyond were similar to previous long-term follow-up data from clinical trials.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    oxaliplatin • irinotecan
    8d
    To investigate the efficacy and safety of irinotecan liposome combined with fluorouracil and oxaliplatin as neoadjuvant therapy for locally advanced rectal cancer (ChiCTR2600117281)
    P=N/A, N=34, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • RAS mutation
    |
    5-fluorouracil • leucovorin calcium
    8d
    Exploratory clinical study of fuquinitinib combined with TAS-102 as a second-line maintenance therapy for patients with metastatic colorectal cancer (ChiCTR2500112655)
    P4, N=40, Not yet recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New P4 trial
    |
    RAS mutation
    |
    Lonsurf (trifluridine/tipiracil)
    8d
    Torametinib for the Treatment of Recurrent/Refractory Pediatric Tumors (ChiCTR2500114659)
    P4, N=28, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University
    New P4 trial
    |
    BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1)
    |
    BRAF V600 • RAS mutation
    |
    Loqtorzi (toripalimab-tpzi)
    8d
    Trifluridine-Tipiracil plus Fruquintinib vs Trifluridine-Tipiracil plus Bevacizumab for Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority trial (TAS-FUR) (ChiCTR2500112138)
    P4, N=236, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P4 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    9d
    Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors. (PubMed, Cancer Res Commun)
    No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in MSS mCRC patients treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.
    Journal • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
    |
    BRAF mutation • RAS mutation
    9d
    DDU RAF/MEK: Phase I Trial of VS-6766 Alone and in Combination With Everolimus (clinicaltrials.gov)
    P1, N=104, Completed, Royal Marsden NHS Foundation Trust | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation
    |
    everolimus • Avmapki (avutometinib)
    9d
    Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study. (PubMed, ESMO Open)
    First-line treatment with tislelizumab plus XELOX and bevacizumab demonstrated a high ORR and a manageable safety profile in patients with MSS/pMMR, RAS-mutant mCRC. This chemo-immunotherapy combination represents a promising strategy and warrants further investigation in a phase III trial.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • pMMR
    |
    RAS (Rat Sarcoma Virus)
    |
    RAS mutation
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    10d
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=266, Recruiting, Beijing Tide Pharmaceutical Co., Ltd
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • RAS mutation • RET mutation • MET mutation
    |
    Lynparza (olaparib) • topotecan • Andewei (benmelstobart)
    11d
    Prognostic Impact of RAS and TP53 Mutation Profiles in Metastatic Colorectal Cancer. (PubMed, Medicina (Kaunas))
    The RASm/TP53w mutation profile was identified as an independent prognostic factor for decreased OS. These findings are expected to contribute to the literature as real-world evidence regarding the prognostic value of different RAS and TP53 mutation combinations in mCRC.
    Journal
    |
    TP53 (Tumor protein P53) • RAS (Rat Sarcoma Virus)
    |
    TP53 mutation • RAS mutation